![Comprehensive molecular profiles of the most common cancer types are now available. [NHGRI]](https://www.clinicalomics.com/wp-content/uploads/2019/01/74-218x150.jpeg "Tempus Gets CE Mark for its Broad-Panel Genomic Sequencing Test")
![Inova's whole genome sequencing test and interpretation from Veritas Genetics will be offered through the MyMap genetic information service. [© Anetta/Fotolia]](https://www.clinicalomics.com/wp-content/uploads/2019/01/1269-356x220.jpeg "Inova, Veritas Genetics Partner to Combine WGS, Interpretation Services")
Innovator: If ‘Overall’ Underwhelms, Turn to RNA-Seq
RNA-seq is helping researchers take a fresh look at gene expression and its relationship to biological phenomena.
Illumina to Acquire GenoLogics Life Sciences Software
Illumina said today it will acquire GenoLogics Life Sciences Software, a developer of laboratory information management systems (LIMS) for life science organizations, in a...
Tumor-Only Sequences Riddled with Mutational False-Positives
Many of the mutations that are found with tumor-only genetic sequencing are not actually tumor-related. Instead, they are just germline mutations, which are inherited...
Google-Developed DeepVariant Included on DNAnexus Platform
DNAnexus taps the open-source variant calling tool on its cloud-based platform through a pilot program to serve its broad range of customers
Researchers ID Disease-Causing Mutations in the Exome That Alter Gene Splicing
To help identify disease-causing variants in the genome, researchers developed a tool that works by producing artificial “minigenes.”
NIH to Evaluate Use of Genomics to Inform Chronic Disease Treatment
The NIH plans to spend $42 million over five years to fund clinical trials designed to evaluate whether and how the management of diseases...
The Broad, Dana-Farber Launch Metastatic Prostate Cancer Project
Initiative designed to encourage men with the disease in the U.S. and Canada to share their data with researchers studying the disease
Asymptomatic People Infected with SARS-CoV-2 May Have Weaker Immune Response to Virus
The researchers from Chongqing Medical University in Chongqing, China, also found that people’s antibody response to SARS-CoV-2 may diminish rapidly after infection, which may have implications for the interpretation of negative serological results.
CRISPR Comes of Age—As a Diagnostic
Hailed for its gene editing power, Sherlock Bioscience’s COVID-19 diagnostic is the first CRISPR technology to gain FDA approval.Hailed for its gene editing power, Sherlock Bioscience’s COVID-19 diagnostic is the first CRISPR technology to gain FDA approval.
Agios Gains FDA Approval for Precision AML Drug
Tibsovo gains approval for adult patients with relapsed or refractory acute myeloid leukemia with specific mutations in the IDH1 gene
